Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 122, Issue 2, Pages 481-484Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI61345
Keywords
-
Categories
Funding
- NIAID NIH HHS [R37AI044628, R01 AI081848, R37 AI044628, R01AI081848] Funding Source: Medline
Ask authors/readers for more resources
Imiquimod is a TLR agonist that is used as an antitumor agent, mainly against skin tumors. Its clinical benefits are well described in several studies; however, the mechanisms behind its antitumor effects are not completely understood. In this issue of the JCI, Drobits and colleagues demonstrate that topical application of imiquimod suppresses cutaneous melanoma by TLR7-dependent recruitment and transformation of plasmacytoid dendritic cells into killer cells; this occurs independently of conventional adaptive immune mechanisms.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available